The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia

Journal of Clinical Psychiatry

Volumn 61, Issue SUPPL. 3, 2000, Pages 4-9

  Keck Jr , Paul E ^a   Strakowski, Stephen M ^a   McElroy, Susan L ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CLOZAPINE; FLUOXETINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGGRESSION; ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; HOSTILITY; HUMAN; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SUICIDAL BEHAVIOR; VIOLENCE;

AGGRESSION; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLINICAL TRIALS; CLOZAPINE; DEPRESSION; DEPRESSIVE DISORDER; DIBENZOTHIAZEPINES; HOSTILITY; HUMANS; MULTICENTER STUDIES; PIPERAZINES; PIRENZEPINE; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUICIDE; THIAZOLES; TREATMENT OUTCOME;

EID: 0342288642     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Siris SG. Depression and schizophrenia. In: Hirsch SR, Weinberger DR, eds. Schizophrenia. Oxford, England: Blackwell Science; 1995:128-145
2. Hirsch ST, Jolley AG. The dysphoric syndrome in schizophrenia and its implications for relapses. Br J Psychiatry 1989;155(suppl 5):45-50
3. Johnson DAW. The significance of depression in the prediction of relapse in chronic schizophrenia. Br J Psychiatry 1988;152:320-323
4. Martin RL, Cloninger CR, Guze SB, et al. Frequency and differential diagnosis of depressive syndromes in schizophrenia. J Clin Psychiatry 1985;46 (11, sec 2):9-13
5. Harrow M, Yonan CA, Sands JR, et al. Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophr Bull 1994;20: 327-338
6. Robins LN, Regier DA, eds. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: The Free Press; 1991
7. Strakowski SM. The co-occurrence of depression in schizophrenia. In: Keck PE Jr, ed. Managing the Depressive Symptoms of Schizophrenia. London, England: Science Press. In press
8. Judd LL. Mood disorders in schizophrenia: epidemiology and comorbidity. J Clin Psychiatry Monograph 1998;16(1):2-4
9. Koreen AR, Siris SG, Chakos M, et al. Depression in first-episode schizophrenia. Am J Psychiatry 1993;150:1643-1648
10. Birchwood M, Mason R, MacMillan F, et al. Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis. Psychol Med 1993;23: 387-395
11. Roy A, Thompson R, Kennedy S. Depression in chronic schizophrenia. Br J Psychiatry 1983;142:465-470
12. The Special Hospitals Treatment Resistant Schizophrenia Research Group. Schizophrenia, violence, clozapine and risperidone: a review. Br J Psychiatry 1996;169(suppl 31):21-30
13. Miles C. Conditions predisposing to suicide: a review. J Nerv Ment Dis 1977;164:221-246
14. Caldwell CB, Gottesman H. Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull 1990;16:571-589
15. Roy A. Suicide in chronic schizophrenia. Br J Psychiatry 1982;141: 171-177
16. Roy A. Depression, attempted suicide, and suicide in patients with chronic schizophrenia. Psychiatr Clin North Am 1986;9:193-206
17. Drake RE, Cotton PG. Depression, hopelessness and suicide in chronic schizophrenia. Br J Psychiatry 1986;148:554-559
18. Prasad AJ, Kumar N. Suicidal behavior in hospitalized schizophrenics. Suicide Life Threat Behav 1988;18:265-269
19. Barnes TR, Curson DA, Liddle PE, et al. The nature and prevalence of depression in chronic schizophrenic in-patients. Br J Psychiatry 1989;154: 486-491
20. Swanson JW, Holzer CE, Ganju VK, et al. Violence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment Area Surveys. Hosp Community Psychiatry 1990;41:761-770
21. Link B, Andrews H, Cullen FT. The violent and illegal behavior of mental patients reconsidered. Am Suicide Rev 1992;57:275-292
22. Lindqvist P, Allbeck P. Schizophrenia and crime: a longitudinal follow-up of 644 schizophrenics in Stockholm. Br J Psychiatry 1990;159:345-350
23. Hodgins S. Mental disorder, intellectual deficiency and crime. Arch Gen Psychiatry 1992;49:476-483
24. Coid B, Lewis S, Reveley AM. A twin study of psychosis and criminality. Br J Psychiatry 1993;163:87-92
25. Taylor PJ. Schizophrenia and crime: distinctive patterns in association. In: Hodgins S, ed. Crime and Mental Disorder. Beverly Hills, Calif: Sage; 1993:63-85
26. Wessely SC, Castle D, Douglas AJ, et al. The criminal careers of incident cases of schizophrenia. Psychol Med 1994;24:483-502
27. Taylor PJ. Motives for offending among violent and psychotic men. Br J Psychiatry 1985;147:491-498
28. Link B, Stueve A. Psychiatric symptoms and the violent/illegal behavior of mental patients compared to community controls. In: Monahan J, Steadman H, eds. Violence and Mental Disorder. Chicago, Ill: University of Chicago Press; 1994
29. Johnstone EC, Crow TJ, Johnson AL, et al. The Northwick Park Study of first episode of schizophrenia. Br J Psychiatry 1986;148:115-143
30. Humphreys HS, Johnstone EC, MacMillan JF, et al. Dangerous behavior preceding first admission for schizophrenia. Br J Psychiatry 1992;161: 501-505
31. Taylor PJ, Gunn J. Violence and psychosis. BMJ 1984;288:1945-1949
32. Keck PE Jr, McElroy SL. The new antipsychotics and their therapeutic potential. Psychiatr Ann 1997;27:320-331
33. McElroy SL, Dessam EC, Pope HG Jr, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry 1991;52:411-414
34. Banov MD, Zarate CA Jr, Tohen M, et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994;55:295-300
35. Calabrese JR, Kimmel SE, Woyshville MJ. et al. Clozapine for treatment-refractory mania. An J Psychiatry 1996;153:759-764
36. Suppes T, McElroy SL Gilbert J, et al. Clozapine in the treatment of dysphoric mania. Biol Psychiatry 1992;32:270-280
37. Suppes T, Phillips KA, Judd DR. Clozapinc treatment of nonpsychotic rapid cycling bipolar disorder: a report of three cases. Biol Psychiatry 1994;36: 338-340
38. Zarate CA Jr, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995;56:411-417
39. Keck PE Jr, McElroy SL, Strakowski SM, et al. Pharmacologic treatment of schizoaffective disorder. Psychopharmacology (Berl) 1994;114:529-538
40. Naber D, Hippius H. The European experience with the use of clozapine. Hosp Community Psychiatry 1990;41:886-890
41. Tran PV, Hamilton SH, Kuntz AJ. et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
42. Müller-Seicheneder F, Müller MJ, Hillert A. et al. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 1998;18: 111-120
43. Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 1993;26:121-124
44. Hillert A, Maier W, Wetzel H, et al. Risperidone in the treatment of disorders with combined psychotic and depressive syndrome: a functional approach. Pharmacopsychiatry 1992;25:213-217
45. Dwight MM, Keck PE Jr, Stanton SP, et al. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder. Lancet 1994;344:554-555
46. Keck PE Jr, Wilson DR, Strakowski SM, et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 1995;56:466-470
47. Sajatovic M, DiGiovanni SK, Bastani B, et al. Risperidone therapy in the treatment of refractory acute bipolar and schizoaffective mania. Psychopharmacol Bull 1996;32:55-61
48. O'Conner M, Silver H. Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression [letter]. J Clin Psychopharmacol 1998;18:89-91
49. Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia. Arch Gen Psychiatry 1998;55:250-258
50. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective disorder and schizophreniform disorder: results of the international collaborative trial. Am J Psychiatry 1997;154:457-465
51. Rothschild AJ, Bates KS, Boehringer K, et al. Olanzapine response in psychotic depression. In: Scientific Abstracts of the 36th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10, 1997; Honolulu, Hawaii
52. Shelton R, Tollefson G, Tohen M, et al. The study of olanzapine plus fluoxetine in treatment-resistant major depressive disorder without psychotic features. In: Abstracts of the 38th Annual Meeting of the New Clinical Drug Evaluation Unit; June 10-11, 1998; Boca Raton, Fla
53. Weisler RH, Ahearn EP, Davidson JR, et al. Adjunctive use of olanzapine in mood disorders: five case reports. Ann Clin Psychiatry 1997;9:259-262
54. Arvanitis LA, Miller BG, Kowalcyk BB, et al. Efficacy of "Seroquel" (quetiapine fumerate) in affective symptoms of schizophrenia. In: Scientific Abstracts of the 36th Annual Meeting of the American College of Neuropsychopharmacology; Dec 8, 1997; Honolulu, Hawaii
55. Keck PE Jr, Harrigan EP, Reeves KR. The efficacy of ziprasidone in schizophrenia and schizoaffective disorder: an update [abstract]. Biol Psychiatry 1997;42(suppl):42S
56. Keck PE Jr, Reeves KR, Harrigan EP. Ziprasidone: an overview of efficacy and tolerability in the treatment of patients with acute exacerbation of schizophrenia or schizoaffective disorder. In: Abstracts of the 37th Annual Meeting of the New Clinical Drug Evaluation Unit; May 27-30, 1997; Boca Raton, Fla
57. Fava M. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am 1997;20:427-450
58. Buckley PF, Ibrahim ZY, Singer B, et al. Aggression and schizophrenia: efficacy of risperi done. J Am Acad Psychiatry Law 1997;25:173-181
59. Balassa M, Deisenhammer E, Schever H. Clozapine, ein nicht ketaleptagenes neuroleptikum, in der behandlung von verhaltenssturngen mit erregangszustanden. Wiener Med Wachenschrift 1971;121:90-92
60. Maier GJ. The impact of clozapine on 25 forensic patients. Bull Am Acad Psychiatry Law 1992;20:297-307
61. Ebrahim GM, Gibler B, Gacono CB, et al. Patient response to clozapine in a forensic psychiatric hospital. Hosp Community Psychiatry 1994;45: 271-273
62. Chiles JA, Davidson P, McBride D. Effects of clozapine on use of seclusion and restraint at a state hospital. Hosp Community Psychiatry 1994;45: 269-271
63. Wilson WH. Clinical review of clozapine treatment in a state hospital. Hosp Community Psychiatry 1992;43:700-703
64. Ratey JJ, Leveroni C, Kilmer D, et al. The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. J Clin Psychiatry 1993; 54:219-223
65. Buckley P, Bartell J, Donenwirth K, et al. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995;23:607-611
66. Spivak B, Mester R, Wittenberg N, et al. Reduction of aggressiveness and impulsiveness during clozapine treatment in chronic neuroleptic-resistant schizophrenic patients. Clin Neuropharmacol 1997;20:442-446
67. Hector RI. The use of clozapine in the treatment of aggressive schizophrenia. Can J Psychiatry 1998;43:466-472
68. Rabinovitz J, Avnon M, Rosenberg V. Effect of clozapine on physical and verbal aggression. Schizophr Res 1996;22:249-255
69. Czobor P, Volavka J, Meibach R. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995;15:243-249
70. Beck NC, Greenfield SR, Gotham H, et al. Risperidone in the management of violent, treatment-resistant schizophrenics hospitalized in a maximum security forensic facility. J Am Acad Psychiatry Law 1997;25:461-468
71. Beasley CM, Sayler ME, Kiesler GM, et al. The influence of pharmacotherapy on self-directed and externally-directed aggression in schizophrenia [abstract]. Schizophr Res 1998;29:28
72. Street J, Mitan S, Tamura R, et al. Olanzapine in the treatment of psychosis and behavioral disturbances associated with Alzheimer's disease. Presented at the 3rd Congress of the European Federation of Neurological Societies; Sept 19-25, 1998; Seville, Spain
73. Borison RL, Arvanitis LA, Miller BG, et al. ICI 204, 636, an atypical anti-psychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16:158-169
74. Cantillon M, Arvanitis LA, Miller BG, et al. "Seroquel" (quetiapine fumarate) reduces hostility and aggression in patients with acute schizophrenia. Presented at the 36th Annual Meeting of the American College of Neuropsychopharmacology; Dec 8-12, 1997; Honolulu, Hawaii
75. Brook S, Krams M, Gunn KP, et al. The efficacy and tolerability of intramuscular (i.m.) ziprasidone versus i.m. haloperidol in patients with acute, non-organic psychosis. Presented at the 10th annual meeting of the European College of Neuropsychopharmacology; Sept 1997; Austria Centre, Austria
76. Reeves KR, Swift RH, Harrigan EP. A comparison of rapid-acting, intramuscular (i.m.) ziprasidone 2 mg and 20 mg in patients with psychosis and acute agitation. Presented at the Annual Meeting of the Collegium Internationale Neuropsychopharmacologium; July 1998; Glasgow, Scotland
77. Meltzer HY. Suicide in schizophrenia: risk factors and clozapine treatment. J Clin Psychiatry 1998;59(suppl 3):15-20
78. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-190
79. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1997;8:671-677
80. Glazer WM. Formulary decisions and health economics. J Clin Psychiatry 1998;59(suppl 19):23-29